Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: A longitudinal observation in mechanically ventilated patients

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1341-1350

  Reinhardt, Anita ^a   Köhler, Thilo ^a   Wood, Paul ^a   Rohner, Peter ^b   Dumas, Jean Luc ^a   Ricou, Bara ^b   Van Delden, Christian ^a,b,c  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Service des Maladies Infectieuses   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; NORFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

AMPC GENE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIUM ISOLATE; BRONCHITIS; CASE REPORT; GENE EXPRESSION; GRAM NEGATIVE INFECTION; HUMAN; HUMAN CELL; MEXC GENE; OPRD GENE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; TRACHEOTOMY; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; HUMANS; LONGITUDINAL STUDIES; PNEUMONIA, VENTILATOR-ASSOCIATED; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 34247092332     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01278-06     Document Type: Article

References (48)

1. Boffi El Amari, E., E. Chamot, R. Auckenthaler, J. C. Pechère, and C. Van Delden. 2001. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin. Infect. Dis. 33:1859-1864.
2. Campbell, J. I., O. Ciofu, and N. Hoiby. 1997. Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different β-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region. Antimicrob. Agents Chemother. 41:1380-1384.
3. Chamot, E., E. Boffi El Amari, P. Rohner, and C. Van Delden. 2003. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47:2756-2764.
4. Chastre, J., and J. Y. Fagon. 2002. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165:867-903.
5. Chastre, J., C. E. Luyt, A. Combes, and J. L. Trouillet. 2006. Use of quantitative cultures and reduced duration of antibiotic regimens for patients with ventilator-associated pneumonia to decrease resistance in the intensive care unit. Clin. Infect. Dis. 43(Suppl. 2):S75-S81.
6. Chastre, J., M. Wolff, J. Y. Fagon, S. Chevret, F. Thomas, D. Wermert, E. Clementi, J. Gonzalez, D. Jusserand, P. Asfar, D. Perrin, F. Fieux, and S. Aubas. 2003. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588-2598.
7. Crouch Brewer, S., R. G. Wunderink, C. B. Jones, and K. V. Leeper, Jr. 1996. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109:1019-1029.
8. Dumas, J. L., C. Van Delden, K. Perron, and T. Köhler. 2006. Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol. Lett. 254:217-225.
9. Epp, S. F., T. Köhler, P. Plésiat, M. Michea-Hamzehpour, J. Frey, and J. C. Pechère. 2001. C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem. Antimicrob. Agents Chemother. 45:1780-1787.
10. George, D. L., P. S. Falk, R. G. Wunderink, K. V. Leeper, Jr., G. U. Meduri, E. L. Steere, C. E. Corbett, and C. G. Mayhall. 1998. Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. Am. J. Respir. Crit. Care Med. 158:1839-1847.
11. Giwercman, B., P. A. Lambert, V. T. Rosdahl, G. H. Shand, and N. Hoiby. 1990. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. J. Antimicrob. Chemother. 26:247-259.
12. Giwercman, B., C. Meyer, P. A. Lambert, C. Reinert, and N. Hoiby. 1992. High-level β-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrob. Agents Chemother. 36:71-76.
13. Häussler, S., B. Tümmler, H. Weissbrodt, M. Rohde, and I. Steinmetz. 1999. Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin. Infect. Dis. 29:621-625.
14. Häussler, S., I. Ziegler, A. Lottel, F. von Gotz, M. Rohde, D. Wehmhohner, S. Saravanamuthu, B. Tümmler, and I. Steinmetz. 2003. Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J. Med. Microbiol. 52:295-301.
15. Higgins, P. G., A. C. Fluit, D. Milatovic, J. Verhoef, and F. J. Schmitz. 2003. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 21:409-413.
16. Hocquet, D., P. Nordmann, F. El Garch, L. Cabanne, and P. Plésiat. 2006. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1347-1351.
17. Holloway, B. W., V. Krishnapillai, and A. F. Morgan. 1979. Chromosomal genetics of Pseudomonas. Microbiol. Rev. 43:73-102.
18. Ibrahim, E. H., G. Sherman, S. Ward, V. J. Fraser, and M. H. Kollef. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146-155.
19. Jalal, S., O. Ciofu, N. Hoiby, N. Gotoh, and B. Wretlind. 2000. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 44:710-712.
20. Jalal, S., and B. Wretlind. 1998. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb. Drug Resist. 4:257-261.
21. Join-Lambert, O. F., M. Michea-Hamzehpour, T. Köhler, F. Chau, F. Faurisson, S. Dautrey, C. Vissuzaine, C. Carbon, and J. Pechère. 2001. Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats. Antimicrob. Agents Chemother. 45:571-576.
22. Köhler, T., M. Michea-Hamzehpour, P. Plésiat, A. L. Kahr, and J. C. Pechère. 1997. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:2540-2543.
23. Kollef, M. H. 1999. Avoidance of tracheal intubation as a strategy to prevent ventilator-associated pneumonia. Intensive Care Med. 25:553-555.
24. Langaee, T. Y., L. Gagnon, and A. Huletsky. 2000. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC β-lactamase expression. Antimicrob. Agents Chemother. 44:583-589.
25. Langford, P. R., H. Anwar, I. Gonda, and M. R. Brown. 1989. Outer membrane proteins of gentamicin induced small colony variants of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 52:33-36.
26. Levine, S. A., and M. S. Niederman. 1991. The impact of tracheal intubation on host defenses and risks for nosocomial pneumonia. Clin. Chest Med. 12:523-543.
27. Livermore, D. M. 1997. β-Lactamases: quantity and resistance. Clin. Microbiol. Infect. 3(Suppl. 4):S10-S19.
28. Livermore, D. M. 1992. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:2046-2048.
29. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
30. Lomovskaya, O., A. Lee, K. Hoshino, H. Ishida, A. Mistry, M. S. Warren, E. Boyer, S. Chamberland, and V. J. Lee. 1999. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1340-1346.
31. Lomovskaya, O., M. S. Warren, A. Lee, J. Galazzo, R. Franko, M. Lee, J. Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins, K. Hoshino, H. Ishida, and V. J. Lee. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45:105-116.
32. Mahenthiralingam, E., M. E. Campbell, J. Foster, J. S. Lam, and D. P. Speert. 1996. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J. Clin. Microbiol. 34:1129-1135.
33. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327.
34. Mehta, R. M., and M. S. Niederman. 2003. Nosocomial pneumonia in the intensive care unit: controversies and dilemmas. J. Intensive Care Med. 18:175-188.
35. National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing, vol. 24, no. 1. National Committee for Clinical Laboratory Standards, Wayne, PA.
36. Niederman, M. S. 2006. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin. Infect. Dis. 42(Suppl. 2):S72-S81.
37. Niederman, M. S., D. E. Craven, M. Bonten, J. Chastre, W. A. Craig, J. Y. Fagon, J. Hall, G. A. Jacoby, M. H. Kollef, C. M. Luna, L. A. Mandell, A. Torres, and R. G. Wunderink. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
38. Normark, B. H., and S. Normark. 2002. Evolution and spread of antibiotic resistance. J. Intern. Med. 252:91-106.
39. Oh, H., J. Stenhoff, S. Jalal, and B. Wretlind. 2003. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb. Drug Resist. 9:323-328.
40. Pfaffl, M. W., G. W. Horgan, and L. Dempfle. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e36.
41. Rello, J., D. Mariscal, F. March, P. Jubert, F. Sanchez, J. Vallès, and P. Coll. 1998. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients. Relapse or reinfection? Am. J. Respir. Crit. Care Med. 157:912-916.
42. Renau, T. E., R. Leger, E. M. Flamme, J. Sangalang, M. W. She, R. Yen, C. L. Gannon, D. Griffith, S. Chamberland, O. Lomovskaya, S. J. Hecker, V. J. Lee, T. Ohta, and K. Nakayama. 1999. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J. Med. Chem. 42:4928-4931.
43. Sobel, M. L., G. A. McKay, and K. Poole. 2003. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 47:3202-3207.
44. Trouillet, J. L., A. Vuagnat, A. Combes, N. Kassis, J. Chastre, and C. Gibert. 2002. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin. Infect. Dis. 34:1047-1054.
45. Vincent, J. L., D. J. Bihari, P. M. Suter, H. A. Bruining, J. White, M. H. Nicolas-Chanoin, M. Wolff, R. C. Spencer, and M. Hemmer. 1995. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA 274:639-644.
46. Vogne, C., J. R. Aires, C. Bailly, D. Hocquet, and P. Plésiat. 2004. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:1676-1680.
47. Wolter, D. J., N. D. Hanson, and P. D. Lister. 2004. Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol. Lett. 236:137-143.
48. Yoneyama, H., and T. Nakae. 1993. Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37:2385-2390.